Painteq v. Omnia Medical: Surgical Cannula Design Patent Settled After 1,537 Days
Painteq, LLC brought a patent infringement action against Omnia Medical, LLC in Florida’s Middle District over a design patent covering a surgical cannula. After more than four years of litigation, the parties reached a full settlement — with dismissal converting to with-prejudice finality after 60 days.
Four-Year Surgical Cannula Design Dispute Ends in Confidential Settlement
Painteq, LLC filed suit against Omnia Medical, LLC on November 30, 2020, in the U.S. District Court for the Middle District of Florida (Case No. 8:20-cv-02805). The action centered on alleged infringement of USD0905232S, a design patent covering the ornamental appearance of a surgical cannula — a device used to create minimally invasive access points during surgery. Design patent disputes in the medical device space often turn on subtle visual distinctions in product form, making them commercially significant despite a single asserted patent.
The case resolved through mediation, with the court dismissing the action on February 14, 2025, initially without prejudice. Under the court’s order, the parties had 60 days to submit a stipulated final order or judgment, extend the deadline, or move to reopen on good cause — a structured exit mechanism that automatically converts to dismissal with prejudice absent further action. The ‘Case Settled’ basis of termination, combined with the mediation-triggered dismissal, indicates the parties reached a comprehensive commercial resolution, though specific terms remain undisclosed.
The 1,537-day duration — over four years — is notably long for a single-patent design infringement case, suggesting the dispute involved contested factual issues, potentially significant commercial stakes, or protracted settlement negotiations. The deployment of six law firms across both sides is consistent with a hard-fought litigation. The public record does not reveal the financial terms of settlement, any licensing arrangement, or whether either party’s product line was affected by the resolution.
Filing to Case Settled in 1537 days
1,537 days — well above the median district court patent case duration of roughly 700–900 days
Case settled via mediation: what the dismissal structure means for both parties
Conditional dismissal without prejudice — with a 60-day conversion clock
The court dismissed the case without prejudice upon receiving the mediator’s report confirming full settlement. Critically, the order included an automatic conversion provision: unless a stipulated final order, extension request, or motion to reopen is filed within 60 days, the dismissal converts to with prejudice. This mechanism is a common judicial tool to finalise settlements while preserving a brief window for parties to memorialize agreed terms in a court order if commercially required.
Mediation-triggered dismissalPainteq secures settlement — enforceability of USD0905232S preserved
As the patent holder, Painteq exits litigation having avoided an adverse invalidity ruling against USD0905232S. A settlement, particularly one reached after extensive litigation, suggests Omnia Medical acknowledged sufficient risk to negotiate rather than litigate to judgment. The design patent remains valid and enforceable. Painteq retains the right to assert it against other parties — assuming no license-back or covenant-not-to-sue was part of the confidential terms.
Patent remains enforceableOmnia Medical resolves exposure — but settlement terms shape future risk
Omnia Medical avoided a potentially adverse jury verdict on design patent infringement, which can carry substantial damages including lost profits or total profit disgorgement under 35 U.S.C. § 289. By settling, it also avoided a permanent injunction risk. However, the confidential settlement terms likely govern Omnia’s continued product activity. If a license was granted, Omnia may continue selling the cannula; if not, its design may need to be modified or discontinued.
Infringement exposure resolvedDesign patents in surgical tools carry real enforcement weight
This case reinforces that design patents covering surgical device aesthetics — often underestimated — can sustain four-plus years of litigation and compel settlement. For medical device companies, the case signals that ornamental design registrations in the cannula and minimally invasive surgery space warrant monitoring. Competitors producing visually similar access devices should assess FTO exposure against Painteq’s design portfolio, as USD0905232S remains active post-settlement.
Design patent enforcement signalFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Painteq, LLC | Company | Medical device IP holder — holder of USD0905232S surgical cannula design patentSearch in Eureka ↗ |
| Defendant | Omnia Medical, LLC | Company | Omnia Medical, LLC — medical device company accused of infringing surgical cannula designSearch in Eureka ↗ |
| Plaintiff counsel | Andriy Lytvyn | Attorney | Counsel for Painteq, LLCSearch in Eureka ↗ |
| Plaintiff counsel | David L. Luikart , III | Attorney | Counsel for Painteq, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Gregory P. Brown | Attorney | Counsel for Painteq, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Ryan James Leuthauser | Attorney | Counsel for Painteq, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Ryan M. Guerin | Attorney | Counsel for Painteq, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Stephen E. Kelly | Attorney | Counsel for Painteq, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Thomas James Banks | Attorney | Counsel for Painteq, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Hill Ward & Henderson PA | Law Firm | Representing Painteq, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Shumaker, Loop & Kendrick, LLP | Law Firm | Representing Painteq, LLCSearch in Eureka ↗ |
| Defendant counsel | Anna Alston Merritt | Attorney | Counsel for Omnia Medical, LLCSearch in Eureka ↗ |
| Defendant counsel | E.A. Mills , Jr. | Attorney | Counsel for Omnia Medical, LLCSearch in Eureka ↗ |
| Defendant counsel | Jaci L. Overmann | Attorney | Counsel for Omnia Medical, LLCSearch in Eureka ↗ |
| Defendant counsel | Jessica Skoglund Mazariego | Attorney | Counsel for Omnia Medical, LLCSearch in Eureka ↗ |
| Defendant counsel | Lee B Bennin | Attorney | Counsel for Omnia Medical, LLCSearch in Eureka ↗ |
| Defendant counsel | Loren L. Hansen | Attorney | Counsel for Omnia Medical, LLCSearch in Eureka ↗ |
| Defendant counsel | Luca Lee Hickman | Attorney | Counsel for Omnia Medical, LLCSearch in Eureka ↗ |
| Defendant counsel | Matthew G. Davis | Attorney | Counsel for Omnia Medical, LLCSearch in Eureka ↗ |
| Defendant counsel | Ralph Edward Cascarilla | Attorney | Counsel for Omnia Medical, LLCSearch in Eureka ↗ |
| Defendant law firm | Dinsmore & Shohl LLP | Law Firm | Representing Omnia Medical, LLCSearch in Eureka ↗ |
| Defendant law firm | Jimerson Birr, P.A. | Law Firm | Representing Omnia Medical, LLCSearch in Eureka ↗ |
| Defendant law firm | Lathrop Gpm LLP | Law Firm | Representing Omnia Medical, LLCSearch in Eureka ↗ |
| Defendant law firm | Mills Law Group | Law Firm | Representing Omnia Medical, LLCSearch in Eureka ↗ |
| Defendant law firm | Paskert Divers Thompson | Law Firm | Representing Omnia Medical, LLCSearch in Eureka ↗ |
| Defendant law firm | Walter Haverfield LLP | Law Firm | Representing Omnia Medical, LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Florida Middle District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal order is expressly predicated on the mediator’s confirmation that the case was ‘completely settled,’ signalling a comprehensive resolution rather than a partial or issue-specific agreement. The without-prejudice framing with an automatic 60-day conversion to with-prejudice is a deliberate judicial mechanism: it gives parties time to lodge a consent judgment if needed for enforceability, while ensuring the docket closes permanently. No merits determination was made — USD0905232S’s validity was neither confirmed nor challenged by the court.
USD0905232S — Ornamental Design for a Surgical Cannula
USD0905232S (Application No. US29/737822) is a U.S. design patent protecting the ornamental appearance of a surgical cannula — a hollow tube inserted through the body wall to provide instrument access during minimally invasive surgery. Design patents protect the visual characteristics of a product, not its functional mechanics, making infringement analysis heavily focused on the ‘ordinary observer’ test: whether an ordinary observer, familiar with prior art designs, would be deceived into believing the accused product is the same as the patented design.
In the competitive surgical access device market, where product form is closely tied to brand recognition and clinical familiarity, a granted design patent can provide meaningful market exclusivity. USD0905232S represents Painteq’s effort to protect the specific visual expression of its cannula against copycat products. For competitors and new entrants in the laparoscopic and endoscopic access device segment, this patent represents a live enforcement risk — particularly given Painteq’s demonstrated willingness to litigate for over four years to protect it.
Should you run an FTO analysis against USD0905232S?
Any company designing, manufacturing, or distributing surgical cannulas or similar minimally invasive access devices in the U.S. market should treat USD0905232S as a live clearance risk. Painteq has demonstrated enforcement commitment through four-plus years of active litigation. Design patent infringement analysis under the ordinary observer test can capture products with visual similarities even where functional differences exist — making pre-launch FTO review essential for any cannula or trocar product targeting the U.S. market.
PatSnap Eureka’s FTO Search Agent can map USD0905232S against your product designs and identify prior art relevant to any invalidity arguments you may need. Eureka’s design patent analytics also surface Painteq’s broader filing activity, helping you anticipate continuation or divisional design patents that may extend the family’s reach. Use Eureka to monitor new filings from Painteq and flag any design publications that could affect your product roadmap.
Run a freedom-to-operate analysis on USD0905232S to assess your product’s exposure
Run FTO in Eureka →Similar Design Patent Infringement Cases in Medical Device Litigation
Browse comparable design patent enforcement actions involving surgical instruments and medical access devices in U.S. district courts, including Florida Middle District.
What this case signals for the medical device design patent landscape
A four-year surgical cannula dispute ending in settlement highlights sustained enforcement value of design patents in minimally invasive surgery.
Design patents on surgical devices can anchor multi-year enforcement campaigns
Painteq sustained litigation for over 1,500 days on a single design patent. This is consistent with a broader trend of design patents being used as primary enforcement tools in medical device markets where product appearance closely tracks brand identity and market differentiation. R&D teams developing cannulas or trocars should treat design clearance as mandatory.
Mediation-driven settlements preserve patent validity — a strategic asymmetry
When a design patent case settles rather than proceeding to judgment, the patent survives with no invalidity finding on record. For Painteq, this is the optimal outcome: Omnia Medical cannot point to a court ruling that weakens USD0905232S in future disputes. Third parties in the sector cannot rely on this case as prior art to invalidity arguments.
Painteq v Omnia — key questions answered
The case settled after 1,537 days of litigation. The Florida Middle District Court dismissed the action without prejudice on February 14, 2025, based on a mediator’s report confirming complete settlement. The dismissal automatically converts to with prejudice after 60 days unless the parties file a stipulated final order or move to reopen.
Painteq asserted U.S. Design Patent USD0905232S (Application No. US29/737822), which protects the ornamental appearance of a surgical cannula. Design patents protect a product’s visual characteristics rather than its functional attributes, and infringement is assessed using the ‘ordinary observer’ standard.
The court’s order dismissed the case without prejudice but included a 60-day conversion window. Within that period, either party could submit a stipulated final order, request an extension, or move to reopen on good cause. After 60 days with no further action, the dismissal automatically becomes with prejudice, permanently closing the dispute.
No adverse ruling was made on USD0905232S’s validity or enforceability. Because the case settled without a merits judgment, the patent remains valid and enforceable. Painteq retains the right to assert it against other defendants. Third parties cannot use this case as precedent for invalidity arguments against the patent.
The 1,537-day duration suggests the dispute involved substantial commercial stakes, contested factual or legal issues, or prolonged settlement negotiations. The engagement of six separate law firms by Omnia Medical is consistent with an intensely contested defense. The public record does not disclose the specific issues that drove duration, but design patent cases with significant damages exposure under 35 U.S.C. § 289 frequently produce extended litigation timelines.
PatSnap Eureka searches patents and litigation data to answer instantly.